UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-03, Vol.28 (9), p.1527-1533

2010

Volltextzugriff (PDF)

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

Journal of clinical oncology, 2016-11, Vol.34 (32), p.3921-3930

2016

Volltextzugriff (PDF)

Genome-wide linkage analysis of blood pressure under locus heterogeneity

BMC genetics, 2003-12, Vol.4 Suppl 1 (Suppl 1), p.S78

2003

Volltextzugriff (PDF)

Total hip arthroplasty after core decompression: Time-to-event analysis and risk factors

Chinese medical journal, 2024-08, Vol.137 (16), p.1988-1990

2024

Volltextzugriff (PDF)

A Matching Degree Management Model of Human Body Shape and Fashion Design Based on Big Data Analysis

Scientific programming, 2021-11, Vol.2021, p.1-6

2021

Volltextzugriff (PDF)

ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis

Cancer letters, 2016-10, Vol.381 (1), p.23-30

2016

Volltextzugriff (PDF)

Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling

Scientific reports, 2015-09, Vol.5 (1), p.14404-14404, Article 14404

2015

Volltextzugriff (PDF)

Roles of autophagy in cetuximab-mediated cancer therapy against EGFR

Autophagy, 2010-11, Vol.6 (8), p.1066-1077

2010

Volltextzugriff (PDF)

Recent Progress of Energy-Storage-Device-Integrated Sensing Systems

Nanomaterials (Basel, Switzerland), 2023-02, Vol.13 (4), p.645

2023

Volltextzugriff (PDF)

Enhancement Mechanism of Pt/Pd-Based Catalysts for Oxygen Reduction Reaction

Nanomaterials (Basel, Switzerland), 2023-04, Vol.13 (7), p.1275

2023

Volltextzugriff (PDF)

Comparison of outcomes after total hip arthroplasty between patients with osteonecrosis of the femoral head in Association Research Circulation Osseous stage III and stage IV: a five-year follow-up study

Journal of orthopaedic surgery and research, 2024-03, Vol.19 (1), p.170-170, Article 170

2024

Volltextzugriff (PDF)

One-year unplanned readmission after total hip arthroplasty in patients with osteonecrosis of the femoral head: rate, causes, and risk factors

BMC musculoskeletal disorders, 2023-10, Vol.24 (1), p.1-845, Article 845

2023

Volltextzugriff (PDF)

A novel glycyrrhizin acid-coated stent reduces neointimal formation in a rabbit iliac artery model

Frontiers in pharmacology, 2023-05, Vol.14, p.1159779-1159779

2023

Volltextzugriff (PDF)

Analytical Approach for Load-Carrying Capacity Evaluation of Tibetan Timber Beam-column Joint

International journal of architectural heritage, 2023-10, Vol.17 (10), p.1719-1735

2023

Volltextzugriff (PDF)

Influence of Particle Size and Heating Rate on Decomposition of BC Dry Chemical Fire Extinguishing Powders

Particulate science and technology, 2015-09, Vol.33 (5), p.488-493

2015

Volltextzugriff (PDF)

Rapid Prediction of the Open-Circuit-Voltage of Lithium Ion Batteries Based on an Effective Voltage Relaxation Model

Energies (Basel), 2018-12, Vol.11 (12), p.3444

2018

Volltextzugriff (PDF)

Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α

Molecular cancer, 2007-10, Vol.6 (1), p.63-63, Article 63

2007

Volltextzugriff (PDF)

1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy

PloS one, 2010-12, Vol.5 (12), p.e15823-e15823

2010

Volltextzugriff (PDF)

1, 9-Pyrazoloanthrones Downregulate HIF-1[alpha] and Sensitize Cancer Cells to Cetuximab-Mediated Anti-EGFR Therapy

PloS one, 2010-12, Vol.5 (12), p.e15823

2010

Volltextzugriff (PDF)

Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor–targeted therapy with cetuximab and gefitinib

Cancer letters, 2011-07, Vol.306 (1), p.85-91

2011

Volltextzugriff (PDF)

Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha

Molecular cancer, 2007-10, Vol.6, p.63

2007

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(11)
Humans
(9)
Cell Line, Tumor
(6)
Technology
(6)
Antibodies, Monoclonal, Humanized
(5)
Cancer
(5)
Cetuximab
(5)
Oncology
(5)
Patients
(5)
Phosphorylation
(5)
Antibodies, Monoclonal - Pharmacology
(4)
Antineoplastic Agents - Pharmacology
(4)
Apoptosis
(4)
Female
(4)
Kinases
(4)
Mutation
(4)
Proteins
(4)
Science & Technology - Other Topics
(4)
Tumors
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

Genome-wide linkage analysis of blood pressure under locus heterogeneity

Total hip arthroplasty after core decompression: Time-to-event analysis and risk factors

A Matching Degree Management Model of Human Body Shape and Fashion Design Based on Big Data Analysis

ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis

Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling

Roles of autophagy in cetuximab-mediated cancer therapy against EGFR

Recent Progress of Energy-Storage-Device-Integrated Sensing Systems

Enhancement Mechanism of Pt/Pd-Based Catalysts for Oxygen Reduction Reaction

Comparison of outcomes after total hip arthroplasty between patients with osteonecrosis of the femoral head in Association Research Circulation Osseous stage III and stage IV: a five-year follow-up study

One-year unplanned readmission after total hip arthroplasty in patients with osteonecrosis of the femoral head: rate, causes, and risk factors

A novel glycyrrhizin acid-coated stent reduces neointimal formation in a rabbit iliac artery model

Analytical Approach for Load-Carrying Capacity Evaluation of Tibetan Timber Beam-column Joint

Influence of Particle Size and Heating Rate on Decomposition of BC Dry Chemical Fire Extinguishing Powders

Rapid Prediction of the Open-Circuit-Voltage of Lithium Ion Batteries Based on an Effective Voltage Relaxation Model

Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α

1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy

1, 9-Pyrazoloanthrones Downregulate HIF-1[alpha] and Sensitize Cancer Cells to Cetuximab-Mediated Anti-EGFR Therapy

Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor–targeted therapy with cetuximab and gefitinib

Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha

Aktive Filter

Suchergebnisse filtern